Harmonizing Quality Improvement Metrics Across Global Trial Networks to Advance Paediatric Clinical Trials Delivery.

IF 2 4区 医学 Q4 MEDICAL INFORMATICS Therapeutic innovation & regulatory science Pub Date : 2024-09-01 Epub Date: 2024-06-20 DOI:10.1007/s43441-024-00663-0
Sabah Attar, Angie Price, Collin Hovinga, Breanne Stewart, Thierry Lacaze-Masmonteil, Fedele Bonifazi, Mark A Turner, Ricardo M Fernandes
{"title":"Harmonizing Quality Improvement Metrics Across Global Trial Networks to Advance Paediatric Clinical Trials Delivery.","authors":"Sabah Attar, Angie Price, Collin Hovinga, Breanne Stewart, Thierry Lacaze-Masmonteil, Fedele Bonifazi, Mark A Turner, Ricardo M Fernandes","doi":"10.1007/s43441-024-00663-0","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Despite global efforts to improve paediatric clinical trials, significant delays continue in paediatric drug approvals. Collaboration between research networks is needed to address these delays. This paper is a first step to promote interoperability between paediatric networks from different jurisdictions by comparing drivers for, and content of, metrics about clinical trial conduct.</p><p><strong>Methods: </strong>Three paediatric networks, Institute for Advanced Clinical Trials for Children, the Maternal Infant Child and Youth Research Network and conect4children, have each developed metrics to address delays and create efficiencies. We identified the methodology by which each network identified metrics, described the metrics of each network, and mapped consistency to come to consensus about core metrics that networks could share.</p><p><strong>Results: </strong>Metric selection was driven by site quality improvement in one network (11 metrics), by network performance in one network (13 metrics), and by both in one network (five metrics). The domains of metrics were research capacity/capability, site identification/feasibility, trial start-up, and recruitment/enrolment. The network driven by site quality improvement did not have indicators for capacity/capability or identification/feasibility. Fifteen metrics for trial start up and conduct were identified. Metrics related to site approvals were found in all three networks. The themes for metrics can inform the development of 'shared' metrics.</p><p><strong>Conclusion: </strong>We found disparity in drivers, methodology and metrics. Tackling this disparity will result in a unified approach to addressing delays in paediatric drug approvals. Collaborative work to define inter-operable metrics globally is outlined.</p>","PeriodicalId":23084,"journal":{"name":"Therapeutic innovation & regulatory science","volume":null,"pages":null},"PeriodicalIF":2.0000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11335960/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic innovation & regulatory science","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s43441-024-00663-0","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/20 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"MEDICAL INFORMATICS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Despite global efforts to improve paediatric clinical trials, significant delays continue in paediatric drug approvals. Collaboration between research networks is needed to address these delays. This paper is a first step to promote interoperability between paediatric networks from different jurisdictions by comparing drivers for, and content of, metrics about clinical trial conduct.

Methods: Three paediatric networks, Institute for Advanced Clinical Trials for Children, the Maternal Infant Child and Youth Research Network and conect4children, have each developed metrics to address delays and create efficiencies. We identified the methodology by which each network identified metrics, described the metrics of each network, and mapped consistency to come to consensus about core metrics that networks could share.

Results: Metric selection was driven by site quality improvement in one network (11 metrics), by network performance in one network (13 metrics), and by both in one network (five metrics). The domains of metrics were research capacity/capability, site identification/feasibility, trial start-up, and recruitment/enrolment. The network driven by site quality improvement did not have indicators for capacity/capability or identification/feasibility. Fifteen metrics for trial start up and conduct were identified. Metrics related to site approvals were found in all three networks. The themes for metrics can inform the development of 'shared' metrics.

Conclusion: We found disparity in drivers, methodology and metrics. Tackling this disparity will result in a unified approach to addressing delays in paediatric drug approvals. Collaborative work to define inter-operable metrics globally is outlined.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
统一全球试验网络的质量改进指标,推进儿科临床试验的实施。
背景:尽管全球都在努力改善儿科临床试验,但儿科药物审批仍然严重滞后。要解决这些延误问题,需要研究网络之间开展合作。本文通过比较临床试验行为指标的驱动因素和内容,为促进不同辖区儿科网络之间的互操作性迈出了第一步:三个儿科网络--儿童高级临床试验研究所、母婴儿童和青少年研究网络以及 conect4children--分别制定了指标,以解决延误问题并提高效率。我们确定了每个网络确定衡量标准的方法,描述了每个网络的衡量标准,并绘制了一致性图,以便就网络可共享的核心衡量标准达成共识:结果:在一个网络(11 项指标)中,指标选择的驱动因素是网站质量的提高;在一个网络中,指标选择的驱动因素是网络绩效(13 项指标);在一个网络中,指标选择的驱动因素是两者(5 项指标)。衡量标准的领域包括研究能力/胜任力、研究机构的确定/可行性、试验启动和招募/注册。由研究机构质量改进驱动的网络没有能力/适配性或鉴定/可行性指标。确定了 15 个试验启动和开展的指标。所有三个网络中都有与研究机构批准相关的指标。衡量标准的主题可为制定 "共享 "衡量标准提供参考:我们发现在驱动因素、方法和指标方面存在差异。消除这种差异将有助于采用统一的方法来解决儿科药物审批的延误问题。概述了在全球范围内定义可互操作指标的合作工作。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Therapeutic innovation & regulatory science
Therapeutic innovation & regulatory science MEDICAL INFORMATICS-PHARMACOLOGY & PHARMACY
CiteScore
3.40
自引率
13.30%
发文量
127
期刊介绍: Therapeutic Innovation & Regulatory Science (TIRS) is the official scientific journal of DIA that strives to advance medical product discovery, development, regulation, and use through the publication of peer-reviewed original and review articles, commentaries, and letters to the editor across the spectrum of converting biomedical science into practical solutions to advance human health. The focus areas of the journal are as follows: Biostatistics Clinical Trials Product Development and Innovation Global Perspectives Policy Regulatory Science Product Safety Special Populations
期刊最新文献
Comparison of Product Features and Clinical Trial Designs for the DTx Products with the Indication of Insomnia Authorized by Regulatory Authorities. A Framework for the Use and Likelihood of Regulatory Acceptance of Single-Arm Trials Correction: Advanced Regenerative Medicines for Rare Diseases: A Review of Industry Sponsors Investment Motivations. Latest Developments in “Adaptive Enrichment” Clinical Trial Designs in Oncology Advanced Regenerative Medicines for Rare Diseases: A Review of Industry Sponsors Investment Motivations
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1